HLS Therapeutics Inc.
HLTRF
$3.36
-$0.07-1.98%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 55.84% | 19.12% | 51.76% | 27.35% | 44.03% |
| Total Depreciation and Amortization | 0.53% | 0.05% | -6.37% | -9.44% | -22.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -82.60% | 94.25% | -61.52% | 0.90% | -20.18% |
| Change in Net Operating Assets | 44,900.00% | -37,050.00% | 52.31% | 547.51% | -100.46% |
| Cash from Operations | 103.03% | 64.96% | 82.77% | 355.40% | -14.17% |
| Capital Expenditure | -153.85% | -- | -- | -950.00% | 7.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -107.55% | -- | -- |
| Cash from Investing | -2,330.77% | 81.40% | -108.20% | -950.00% | 7.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -95.67% | -288.69% | -437.82% | -39.90% | 19.72% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -162.78% | 37.81% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -102.26% | 77.19% | -266.86% | -8.08% | 31.70% |
| Foreign Exchange rate Adjustments | 119.61% | -206.67% | 413.68% | 113.94% | -300.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,225.00% | 90.82% | -142.69% | 111.08% | -158.33% |